NASDAQ:FOLDAmicus Therapeutics Stock Price, Forecast & News

$12.85

-0.29 (-2.21 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$12.83

Now: $12.85▼

$13.30

50-Day Range

$10.03

MA: $11.96▼

$13.14

52-Week Range

$6.25

Now: $12.85▼

$13.39

Volume2.46 million shs

Average Volume3.30 million shs

Market Capitalization$3.31 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.29

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Amicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.50, Amicus Therapeutics has a potential upside of 59.5% from its current price of $12.85.
Amount of Analyst Coverage
Amicus Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Amicus Therapeutics has received 473 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amicus Therapeutics has received 311 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amicus Therapeutics has received 60.33% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote “Outperform” if you believe FOLD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Amicus Therapeutics does not currently pay a dividend.
Dividend Growth
Amicus Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,742,062.00 in company stock.
Percentage Held by Insiders
Only 2.50% of the stock of Amicus Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Amicus Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amicus Therapeutics is -9.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amicus Therapeutics is -9.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amicus Therapeutics has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.40 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:FOLD

Previous Symbol

CUSIP03152W10

CIK1178879

Webwww.amicusrx.com

Phone609-662-2000

Debt

Debt-to-Equity Ratio0.50

Current Ratio4.45

Quick Ratio4.31

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$182.24 million

Price / Sales18.17

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.87 per share

Price / Book6.87

Profitability

EPS (Most Recent Fiscal Year)($1.31)

Net Income$-356,390,000.00

Net Margins-155.73%

Return on Equity-63.24%

Return on Assets-37.83%

Miscellaneous

Employees508

Outstanding Shares257,664,000

Market Cap$3.31 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

How has Amicus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 59.6% and is now trading at $12.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amicus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amicus Therapeutics.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Amicus Therapeutics.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. The biopharmaceutical company had revenue of $60.53 million for the quarter, compared to the consensus estimate of $57.21 million. Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%. View Amicus Therapeutics' earnings history.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $257.09 million.

What price target have analysts set for FOLD?

7 Wall Street analysts have issued twelve-month target prices for Amicus Therapeutics' shares. Their forecasts range from $12.50 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $20.50 in the next year. This suggests a possible upside of 59.5% from the stock's current price. View analysts' price targets for Amicus Therapeutics.

What are Wall Street analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:

1. According to Zacks Investment Research, "Amicus realized revenues from sales of its only marketed drug, Galafold in the second quarter. The uptake of Galafold has been strong. The company is on track to achieve its 2019 key priorities, including, Pompe late-stage development program, and the development of the gene-therapy pipeline. With a very successful, now global, commercial precision medicine product in Fabry disease, a late-stage phase III program in late onset Pompe disease and rapidly advancing gene therapy programs for rare diseases in development, the company is well positioned to achieve its target. However, it depends heavily on Galafold sales, which is a concern. Shares of the company have outperformed the industry year to date. Loss estimates narrowed ahead of Q3 earnings. The company has a dismal record of earnings surprises in the recent quarters." (11/4/2019)
2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our current 12-month, $18 price target on shares of Amicus is derived from a 13-year DCF-based, sum-of-the-parts analysis driven by: beta of 1.70; terminal growth rate of 0.5%; risk premium of 4.93%; estimated WACC of 10.8%; and tax rate of 12.5% beginning in FY 2030. Galafold and AT- GAA at 42% each, plus the two Batten disease programs programs at a combined 16%, make up our rNPV. For AT-GAA, we assume a POS of 70%, whereas for CLN6 we assume a 45% POS and assign a 10% POS for CLN3." (8/1/2019)

Has Amicus Therapeutics been receiving favorable news coverage?

News stories about FOLD stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amicus Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAmicus Therapeutics.

Who are some of Amicus Therapeutics' key competitors?

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Exelixis (EXEL), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Cara Therapeutics (CARA) and Micron Technology (MU).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:

Mr. John F. Crowley, Chairman & CEO (Age 52)
Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
Dr. Jay A. Barth, Chief Medical Officer (Age 55)
Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.77%), Redmile Group LLC (9.77%), BlackRock Inc. (8.25%), Morgan Stanley (4.80%), Morgan Stanley (4.80%) and Janus Henderson Group PLC (4.51%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View institutional ownership trends for Amicus Therapeutics.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Jennison Associates LLC, Pictet Asset Management Ltd., Nuveen Asset Management LLC, Sphera Funds Management LTD., AXA, Two Sigma Investments LP, and Wellington Management Group LLP. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Jay Barth, John F Crowley, Margaret G Mcglynn, and Michael Raab. View insider buying and selling activity for Amicus Therapeutics.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Deutsche Bank AG, Fairmount Funds Management LLC, Janus Henderson Group PLC, Assenagon Asset Management S.A., BlackRock Inc., Geode Capital Management LLC, and Asymmetry Capital Management L.P.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for Amicus Therapeutics.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $12.85.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $3.31 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff